{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:31:56Z","timestamp":1740173516501,"version":"3.37.3"},"reference-count":16,"publisher":"Endocrinology Research Centre","issue":"1","license":[{"start":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T00:00:00Z","timestamp":1677283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.probl-endojournals.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":["www.probl-endojournals.ru"],"crossmark-restriction":true},"short-container-title":["Probl Endokrinol (Mosk)"],"abstract":"<jats:p>In the past year, the Federal Project \u201cFight against Diabetes\u201d 2023\u20132030 was developed in detail and submitted in detail and submitted to the Government of the Russian Federation, which will significantly improve the practice of working with patients with diabetes, providing them with maximum availability of medical care, including in updated and technologically re -equipped regional endocrinological centers, reviving the active work of \u201cDiabetes schools\u201d, \u201cDiabetic foot\u201d rooms, diagnostic laboratories, introducing new forms of communication with patients, including using personal assistants of a doctor, continuous technologies for monitoring glycemia, etc.<\/jats:p>","DOI":"10.14341\/probl13261","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T05:58:30Z","timestamp":1677477510000},"page":"4-7","update-policy":"https:\/\/doi.org\/10.14341\/crossmarkpolicy2018","source":"Crossref","is-referenced-by-count":0,"title":["What newly brought endocrinology by the past 2022?"],"prefix":"10.14341","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5634-7877","authenticated-orcid":true,"given":"G. A.","family":"Melnichenko","sequence":"first","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5057-127X","authenticated-orcid":true,"given":"M. V.","family":"Shestakova","sequence":"additional","affiliation":[{"name":"Endocrinology Research Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5458","published-online":{"date-parts":[[2023,2,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Hirsch JS. FDA approves teplizumab: a milestone in type 1 diabetes. Lancet Diabetes Endocrinol. 2023;11(1):18. doi: https:\/\/doi.org\/10.1016\/S2213-8587(22)00351-5","DOI":"10.1016\/S2213-8587(22)00351-5"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. doi: https:\/\/doi.org\/10.1016\/S0140-6736(21)01324-6","DOI":"10.1016\/S0140-6736(21)01324-6"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: FIDELITY pooled analysis. EurHeart J. 2022;43(6):474-484. doi: https:\/\/doi.org\/10.1093\/eurheartj\/ehab777","DOI":"10.1093\/eurheartj\/ehab777"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Juanatey JR, G\u00f3rriz JL, Ortiz A, et al. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med. 2023;55(1):502-513. doi: https:\/\/doi.org\/10.1080\/07853890.2023.2171110","DOI":"10.1080\/07853890.2023.2171110"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Crespo-Trevino R, Schiffman J, Ugradar S, et al. Thyroid dermopathy responds to teprotumumab therapy. Endocrinol Diabetes Metab Case Reports. 2022;2022(10295):143-155. doi: https:\/\/doi.org\/10.1530\/EDM-21-0201","DOI":"10.1530\/EDM-21-0201"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Gadelha M, Bex M, Feelders RA, et al. Randomized trial of osilodrostat for the treatment of cushing disease. J Clin Endocrinol Metab. 2022;107(7):e2882-e2895. doi: https:\/\/doi.org\/10.1210\/clinem\/dgac178","DOI":"10.1210\/clinem\/dgac178"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Fleseriu M, Newell-Price J, Pivonello R, et al. Long-term outcomes of osilodrostat in Cushing\u2019s disease: LINC 3 study extension. Eur J Endocrinol. 2022;187(4):531-541. doi: https:\/\/doi.org\/10.1530\/EJE-22-0317","DOI":"10.1530\/EJE-22-0317"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Walia R, Gupta R, Bhansali A, et al. Molecular imaging targeting corticotropin-releasing hormone receptor for corticotropinoma: A changing paradigm. J Clin Endocrinol Metab. 2021;106(4):1816-1826. doi: https:\/\/doi.org\/10.1210\/clinem\/dgaa755","DOI":"10.1210\/clinem\/dgaa755"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Gadelha MR, Gordon MB, Doknic M, et al. ACROBAT edge: Safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly. J Clin Endocrinol Metab. 2022;106(4):1816-1826. doi: https:\/\/doi.org\/10.1210\/clinem\/dgac643","DOI":"10.1210\/clinem\/dgac643"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Zhao J, Wang S, Markison S, et al. Discovery of paltusotine (CRN00808), a potent, selective, and orally bioavailable non-peptide SST2 agonist. ACS Med Chem Lett. 2023;14(1):66-74. doi: https:\/\/doi.org\/10.1021\/acsmedchemlett.2c00431","DOI":"10.1021\/acsmedchemlett.2c00431"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Sarafoglou K, Barnes CN, Huang M, et al. Tildacerfont in adults with classic congenital adrenal hyperplasia: Results from two phase 2 studies. J Clin Endocrinol Metab. 2021;106(11):e4666-e4679. doi: https:\/\/doi.org\/10.1210\/clinem\/dgab438","DOI":"10.1210\/clinem\/dgab438"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Haqq AM, Chung WK, Dollfus H, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstr\u00f6m syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10(12):859-868. doi: https:\/\/doi.org\/10.1016\/S2213-8587(22)00277-7","DOI":"10.1016\/S2213-8587(22)00277-7"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Auchus RJ, Sarafoglou K, Fechner PY, et al. Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2022;107(3):801-812. doi: https:\/\/doi.org\/10.1210\/clinem\/dgab749","DOI":"10.1210\/clinem\/dgab749"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Chan ML, Qi Y, Larimore K, et al. Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia. Clin Pharmacokinet. 2022;61(2):263-280. doi: https:\/\/doi.org\/10.1007\/s40262-021-01059-1","DOI":"10.1007\/s40262-021-01059-1"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020;382(16):1520-1530. doi: https:\/\/doi.org\/10.1056\/NEJMoa1913805","DOI":"10.1056\/NEJMoa1913805"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi: https:\/\/doi.org\/10.1056\/NEJMoa1912387","DOI":"10.1056\/NEJMoa1912387"}],"container-title":["Problems of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/viewFile\/13261\/10407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T15:06:37Z","timestamp":1677510397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.probl-endojournals.ru\/jour\/article\/view\/13261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,25]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2,25]]}},"URL":"https:\/\/doi.org\/10.14341\/probl13261","relation":{},"ISSN":["2308-1430","0375-9660"],"issn-type":[{"type":"electronic","value":"2308-1430"},{"type":"print","value":"0375-9660"}],"subject":[],"published":{"date-parts":[[2023,2,25]]}}}